MEMORIAL DAY OFFER 50% OFF Premium Subscription Order Now MEMORIAL DAY 50% OFF Subscription >>

No Pain, No Gain.Week 21 On Stock Market Click to watch.

Coherus BioSciences Stock Forecast

NASDAQ:CHRS BUY SELL

$7.54 (-1.57%)

Volume: 867.986k

Closed: May 27, 2022

Hollow Logo Score: -3.075

Coherus BioSciences Stock Forecast

BUY SELL NASDAQ:CHRS
$7.54 (-1.57%)

Volume: 867.986k

Closed: May 27, 2022

Score Hollow Logo -3.075

Coherus BioSciences Company Profile

333 Twin Dolphin Drive

Redwood City CA 94065

650-649-3530

www.coherus.com

Industry: Biotechnology

Sector: Healthcare

Coherus BioSciences

Description

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The company’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the prevention of chemotherapy-induced neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis, as well as to treat ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis; and CHS-5217, a bevacizumab biosimilar candidate to treat metastatic colorectal cancer, non–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate to treat ankylosing spondylitis, Behçet's Disease, Crohn’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and ulcerative colitis. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; license agreement with Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; distribution agreement with Orox Pharmaceuticals B.V.; license agreement with Genentech, Inc.; and license agreements with Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE